JAC Advance Access published online on June 16, 2004
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkh303
© 2004 by The British Society for Antimicrobial Chemotherapy
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Medicine E, Beilinson Campus, Rabin Medical Center, Petah Tiqva 49100, Tel-Aviv, Israel
* To whom correspondence should be addressed. E-mail: liatvidal{at}hotmail.com.
Context: Neutropenia is one of the grave consequences of cancer chemotherapy, and the treatment of neutropenic febrile patients with intravenous (iv) antibiotics has been shown to reduce mortality. Oral therapy could be an alternative approach for selected patients. Objectives: To compare the efficacy of oral antibiotics versus iv antibiotic therapy in febrile neutropenic cancer patients. Data sources: The Cochrane Library, the Cochrane Cancer Network Register of trials, EMBASE, LILACS and MEDLINE, databases for ongoing trials and the conference proceedings of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Study selection: Randomized controlled trials comparing oral antibiotic/s and iv antibiotic/s for the treatment of neutropenic cancer patients with fever. Data collection: Two reviewers independently assessed trial eligibility, methodological quality and extracted all data. Data concerning mortality, treatment failures and adverse events were drawn from included studies assuming an ‘intention-to-treat’ and ‘per-protocol’ basis for the outcome measures whenever possible. Relative risks (RR) with their 95% confidence intervals (CI) for dichotomous data were estimated. Main results: Fifteen trials (median mortality 0, range 0%-8.8%) were included in the analyses. The mortality rate was similar comparing oral and iv antibiotic treatment (RR 0.83, 95% CI 0.49-1.41, 2224 patients). Treatment failure rates were also similar (RR 0.94, 95% CI 0.84-1.05, 15 trials). No significant heterogeneity was shown for the primary outcomes. This effect was stable in a wide range of patients. Quinolones alone or combined with other antibiotics were used with comparable results. Adverse reactions, mostly gastrointestinal, were more common with oral antibiotics. Conclusions: Oral antibiotics may be safely offered to neutropenic patients with fever who are at low risk for mortality.
Review
Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients: a systematic review and meta-analysis of randomized trials
2 Department of Medicine E, Beilinson Campus, Rabin Medical Center, Petah Tiqva 49100, Tel-Aviv, Israel; Sackler Faculty of Medicine, Tel-Aviv University, Ramat-Aviv, Tel-Aviv, Israel
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  F. M. Marti, M. H. Cullen, F. Roila, and On behalf of the ESMO Guidelines Working Group Management of febrile neutropenia: ESMO Clinical Recommendations Ann. Onc., May 1, 2009; 20(suppl_4): iv166 - iv169. [Full Text] [PDF]
|
|
|
|
 |
|
 K. G. Moores Safe and effective outpatient treatment of adults with chemotherapy-induced neutropenic fever Am. J. Health Syst. Pharm., April 1, 2007; 64(7): 717 - 722. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Phillips, R Skinner, and J C Chisholm Treating low-risk febrile neutropenia: Jenny's story Arch. Dis. Child., January 1, 2007; 92(1): 7 - 8. [Full Text] [PDF]
|
|
|
|
 |
|
 M.-J. Ouvrier, J.-C. Thery, and E. Blot Outpatient Oral Antibiotics for Febrile Neutropenic Cancer Patients J. Clin. Oncol., December 10, 2006; 24(35): 5614 - 5614. [Full Text] [PDF]
|
|
|
|
|
|
M. Paesmans and J. Klastersky In Reply J. Clin. Oncol., December 10, 2006; 24(35): 5614 - 5615. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Paul and L. Leibovici Systematic Reviews and Meta-analysis of Febrile Neutropenia Mayo Clin. Proc., September 1, 2005; 80(9): 1122 - 1125. [PDF]
|
|